OverweightNCT07850765
Real-World Patient and Physician Experience With Semaglutide Across Six Emerging Markets
An observational study of Overweight and Obesity, run by Novo Nordisk A/S at 6 sites in 6 countries.
Trial summary
The purpose of this study is to assess semaglutide's impact on daily life from participants and physicians experience. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Overweight, Obesity
- What is being tested?
- Semaglutide
- How many people
- 1,260 participants
- Where
- 6 sitesin 6 countries
- Study dates
- 28 Aug 2026to 31 Aug 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Participants receiving semaglutide for at least 16 weeks are included for secondary database analysis.
Who may be able to join
- Aged 18 years or older
- Currently receiving Wegovy for at least 16 weeks, who at initiation of Wegovy had either: BMI of more than or equal to (≥) 27 to less than (<) 30 kilogram per meter square (kg/m^2) with at least one weight-related comorbidity and BMI of ≥30 kg/m^2
- Not currently involved in a clinical trial for overweight or obesity
Who cannot join
- This is a secondary database analysis
Trial locations and contacts
6 sites in 6 countries.
6 sites in 6 countries
United Arab Emirates1 site
Novo Nordisk Investigational Site
Abu Dhabi
About this study
Official title: sEMa-LIFE: Unveiling Semaglutide's Impact on Daily Life - Patient and Physicians Experience Across Six Emerging Markets
The purpose of this study is to assess semaglutide's impact on daily life from participants and physicians experience.
- Conditions
- Overweight, Obesity
- Being tested
- Semaglutide
- Medical subject headings
- Overweight, Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SemaglutideDrug
This is a retrospective, non-interventional study; therefore, no intervention was administered as part of the study.
| Study group | Role | What they receive |
|---|---|---|
| Obesity PLUS I disease specific programme (DSP) | Patients included in this study were those who had been diagnosed with overweight or obesity and had been initiated on Wegovy (semaglutide) at least 16 weeks prior to the date the DSP survey was conducted. This study is based on a retrospective analysis of existing physician-reported data collected through the DSP survey. Receives: Drug: Semaglutide |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Food Noise Questionnaire (FNQ) score
Food noise assessed retrospectively prior to Wegovy initiation and at data capture using the Food Noise Questionnaire (FNQ). The questionnaire evaluates intrusive and persistent food-related thoughts. Each item is scored 0-5, with a total score range of 0-20. Higher scores indicate greater food noise
Measured: At data capture (Day 1)
Change in Body Weight
Change in body weight (kg) from initiation of Wegovy to data capture. Weight measured prior to Wegovy initiation and at data collection.
Measured: At data capture (Day 1)
Health-Related Quality of Life Measured by EQ-5D-5L
Health-related quality of life assessed using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) index score. The EQ-5D-5L consists of 5 items rated on a 5-point Likert scale that ranges from 1 (no problems) to 5 (extreme problems). Higher index scores indicate better health-related quality of life.
Measured: At data capture (Day 1)
Health Status Measured by EQ Visual Analogue Scale (EQ-VAS)
Participant-rated overall health status measured using the EQ-VAS. Scores range from 0 to 100, where higher scores indicate better perceived health.
Measured: At data capture (Day 1)
Medication Adherence Measured by Adelphi Adherence Questionnaire (ADAQ)
Participant-reported adherence to Wegovy treatment assessed using the Adelphi Adherence Questionnaire (ADAQ). The overall adherence summary score ranges from 0 to 4, with lower scores indicating greater medication adherence.
Measured: At data capture (Day 1)
Number of Participant Satisfaction With Wegovy
Participant satisfaction with Wegovy treatment assessed as less than satisfied, satisfied, or more than satisfied according to perceived treatment performance relative to expectations.
Measured: At data capture (Day 1)
Change in Body Mass Index (BMI)
Change in body mass index (kg/m²) from Wegovy initiation to data capture will be reported
Measured: At data capture (Day 1)
Percent Change in Body Weight
Percentage change in body weight between Wegovy initiation and data capture will be reported.
Measured: At data capture (Day 1)
Number of Participants with Achievement of Weight-Loss Target
Participant-reported achievement of the predefined weight-loss goal (Yes/No). Participants may be classified as having reached or exceeded their target weight loss.
Measured: At data capture (Day 1)
Number of Participants who Concern About Future Weight Gain
Number of Participant concern regarding regaining weight after discontinuation of Wegovy treatment will be reported.
Measured: At data capture (Day 1)
Impact of Wegovy on Weight-Related Burden
Degree to which participants were bothered by their weight before starting Wegovy and at data capture after receiving Wegovy.
Measured: At data capture (Day 1)
Impact of Wegovy on Daily Life and Health Behaviours
Changes in work-life impact, cigarette smoking, shisha smoking, and alcohol consumption since initiation of Wegovy.
Measured: At data capture (Day 1)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Sep 2026
- Study start28 Aug 2026
- Primary completion31 Aug 2026
- Study completion31 Aug 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for OverweightStudies of the same condition, open and under way.
- More trials run by Novo Nordisk A/SThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 1,260 participants (actual)
Sponsor and investigators
- Lead sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Transparency (dept. 2834), Study director, Novo Nordisk A/S
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07850765
- Sponsor's protocol ID
- NN9536-8879
- Status last verified
- Sep 2026
- First submitted
- 23 Sep 2026
- Last updated
- 30 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Study at a glance
From the registry record, last updated by the sponsor on 30 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- sEMa-LIFE: Unveiling Semaglutide's Impact on Daily Life - Patient and Physicians Experience Across Six Emerging Markets
- ClinicalTrials.gov ID
- NCT07850765
- Acronym / sponsor ID
- NN9536-8879
- Conditions
- Overweight, Obesity
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,260 participants (actual)
- Lead sponsor
- Novo Nordisk A/SIndustry (pharma, biotech, devices)
- Study start
- 28 Aug 2026 (actual)
- Primary completion
- 31 Aug 2026 (actual)
- Study completion
- 31 Aug 2026 (actual)
- First posted
- 30 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to assess semaglutide's impact on daily life from participants and physicians experience.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Obesity PLUS I disease specific programme (DSP) | – | Drug: SemaglutidePatients included in this study were those who had been diagnosed with overweight or obesity and had been initiated on Wegovy (semaglutide) at least 16 weeks prior to the date the DSP survey was conducted. This study is based on a retrospective analysis of existing physician-reported data collected through the DSP survey. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Participants receiving semaglutide for at least 16 weeks are included for secondary database analysis.
Key inclusion criteria (3 listed)
- Aged 18 years or older
- Currently receiving Wegovy for at least 16 weeks, who at initiation of Wegovy had either: BMI of more than or equal to (≥) 27 to less than (<) 30 kilogram per meter square (kg/m^2) with at least one weight-related comorbidity and BMI of ≥30 kg/m^2
- Not currently involved in a clinical trial for overweight or obesity
Key exclusion criteria (1 listed)
- This is a secondary database analysis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SemaglutideThis is a retrospective, non-interventional study; therefore, no intervention was administered as part of the study. | Drug | Obesity PLUS I disease specific programme (DSP) |
Primary outcome
Change in Food Noise Questionnaire (FNQ) score
Time frame: At data capture (Day 1)
Food noise assessed retrospectively prior to Wegovy initiation and at data capture using the Food Noise Questionnaire (FNQ). The questionnaire evaluates intrusive and persistent food-related thoughts. Each item is scored 0-5, with a total score range of 0-20. Higher scores indicate greater food noise
Change in Body Weight
Time frame: At data capture (Day 1)
Change in body weight (kg) from initiation of Wegovy to data capture. Weight measured prior to Wegovy initiation and at data collection.
Health-Related Quality of Life Measured by EQ-5D-5L
Time frame: At data capture (Day 1)
Health-related quality of life assessed using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) index score. The EQ-5D-5L consists of 5 items rated on a 5-point Likert scale that ranges from 1 (no problems) to 5 (extreme problems). Higher index scores indicate better health-related quality of life.
Health Status Measured by EQ Visual Analogue Scale (EQ-VAS)
Time frame: At data capture (Day 1)
Participant-rated overall health status measured using the EQ-VAS. Scores range from 0 to 100, where higher scores indicate better perceived health.
Medication Adherence Measured by Adelphi Adherence Questionnaire (ADAQ)
Time frame: At data capture (Day 1)
Participant-reported adherence to Wegovy treatment assessed using the Adelphi Adherence Questionnaire (ADAQ). The overall adherence summary score ranges from 0 to 4, with lower scores indicating greater medication adherence.
Number of Participant Satisfaction With Wegovy
Time frame: At data capture (Day 1)
Participant satisfaction with Wegovy treatment assessed as less than satisfied, satisfied, or more than satisfied according to perceived treatment performance relative to expectations.
Change in Body Mass Index (BMI)
Time frame: At data capture (Day 1)
Change in body mass index (kg/m²) from Wegovy initiation to data capture will be reported
Percent Change in Body Weight
Time frame: At data capture (Day 1)
Percentage change in body weight between Wegovy initiation and data capture will be reported.
Number of Participants with Achievement of Weight-Loss Target
Time frame: At data capture (Day 1)
Participant-reported achievement of the predefined weight-loss goal (Yes/No). Participants may be classified as having reached or exceeded their target weight loss.
Number of Participants who Concern About Future Weight Gain
Time frame: At data capture (Day 1)
Number of Participant concern regarding regaining weight after discontinuation of Wegovy treatment will be reported.
Impact of Wegovy on Weight-Related Burden
Time frame: At data capture (Day 1)
Degree to which participants were bothered by their weight before starting Wegovy and at data capture after receiving Wegovy.
Impact of Wegovy on Daily Life and Health Behaviours
Time frame: At data capture (Day 1)
Changes in work-life impact, cigarette smoking, shisha smoking, and alcohol consumption since initiation of Wegovy.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Sep 2026.
- Individual participant dataSharing planned: Yes. According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Related trials for Overweight
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Transparency (dept. 2834) study director
Novo Nordisk A/S
6 sites in 6 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Overweight and Obesity, run by Novo Nordisk A/S at 6 sites in 6 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 6 sites in Israel, Mexico, Saudi Arabia, South Africa, Turkey (Türkiye) and 1 more country. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Food Noise Questionnaire (FNQ) score (time frame: At data capture (Day 1)). The study lists 12 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Sep 2026.